Purchase Order VA25812P0811
Award Date
12/22/11
Potential Completion Date
12/22/11
Potential Value
$7.9K
Federal Agency
Veterans Integrated Service Network 17
Awardee
Regenesis Biomedical Inc.
Ultimate Awardee
Not listed
NAICS Category
339112 - Surgical and Medical Instrument Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Big Spring, TX 79720, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company that develops and markets noninvasive regenerative medicine products. The $4,820.98 firm-fixed-price purchase order is for Regenesis Biomedical's Provant Therapy System, a patented medical device indicated for palliative treatment of post-operative pain and edema. The contract has a performance period through March 16, 2011 and was not set aside for...
This federal contract award, valued at $3,645.14, was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was issued as a purchase order under Regenesis Biomedical's existing General Services Administration (GSA)...
This federal contract award, valued at $6,937.52, was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is a firm-fixed-price purchase order, with an ultimate completion date of March 18, 2011. No set-aside...
This federal contract award, valued at $7,145.55, was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. This contract appears to be a purchase order under Regenesis Biomedical's existing GSA Schedule 65-II-A contract...
This federal contract award, valued at $4,820.98, was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The contract is for the provision of the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical, to VA medical facilities. The contract was awarded as a purchase order under Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A...
This federal contract award was issued by the Veterans Integrated Service Network 17 (VISN 17), a component of the U.S. Department of Veterans Affairs (VA), to Regenesis Biomedical Inc. The $4,820.98 firm-fixed-price purchase order is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a completion date of February 28, 2011 and does...
This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $7,142.85 firm fixed-price purchase order contract is for the provision of Regenesis Biomedical's Provant Therapy System, a patented noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with any set-aside designations. Regenesis Biomedical,...
This federal contract award to Regenesis Biomedical Inc. was made by the Department of Veterans Affairs (VA) for the provision of the Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The $3,645.14 firm fixed-price purchase order contract has a completion date of June 16, 2011. Regenesis Biomedical is the prime contractor providing its proprietary medical device directly to the VA, with no subcontractors...
This federal contract award was made by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the provision of the Provant Therapy System, a patented noninvasive regenerative medicine product. The $7,142.85 firm-fixed-price purchase order contract is for the palliative treatment of post-operative pain and edema. The contract is part of Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A for medical equipment and...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company, for the provision of the Provant Therapy System, a noninvasive regenerative medicine product. The $4,820.98 firm-fixed-price purchase order contract was awarded on January 10, 2011, with a completion date of February 10, 2011. The contract was awarded under Regenesis Biomedical's General Services Administration (GSA) Schedule 65-II-A for...